Mechanisms of disease: L-arginine in coronary atherosclerosis--a clinical perspective.
Standard
Mechanisms of disease: L-arginine in coronary atherosclerosis--a clinical perspective. / Tousoulis, Dimitris; Böger, Rainer; Antoniades, Charalambos; Siasos, Gerasimos; Stefanadi, Elli; Stefanadis, Christodoulos.
in: NAT CLIN PRACT CARD, Jahrgang 4, Nr. 5, 5, 2007, S. 274-283.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mechanisms of disease: L-arginine in coronary atherosclerosis--a clinical perspective.
AU - Tousoulis, Dimitris
AU - Böger, Rainer
AU - Antoniades, Charalambos
AU - Siasos, Gerasimos
AU - Stefanadi, Elli
AU - Stefanadis, Christodoulos
PY - 2007
Y1 - 2007
N2 - L-arginine is the substrate of endothelial nitric oxide synthase and the main precursor of nitric oxide in the vascular endothelium, thus its effects are mediated largely by increases in nitric oxide production. L-arginine has antioxidant and antiapoptotic properties, increases smooth muscle relaxation, inhibits the expression of adhesion molecules and chemotactic peptides, decreases endothelin-1 expression, and inhibits platelet aggregation. This amino acid also improves endothelial function in patients with coronary artery disease and dilates human epicardial atheromatous coronary arteries. Despite the positive results from small case-control studies, it is still unclear whether chronic administration of L-arginine has any effect on clinical outcome in patients with coronary artery disease. In addition, other indirect strategies, such as the inhibition of arginase, could prove more effective at improving intracellular L-arginine bioavailability than exogenous L-arginine administration. The potential clinical usefulness of L-arginine, therefore, needs further evaluation in large, prospective clinical trials. Here, we present a critique of the existing literature about the role of L-arginine in the prevention of atherosclerosis.
AB - L-arginine is the substrate of endothelial nitric oxide synthase and the main precursor of nitric oxide in the vascular endothelium, thus its effects are mediated largely by increases in nitric oxide production. L-arginine has antioxidant and antiapoptotic properties, increases smooth muscle relaxation, inhibits the expression of adhesion molecules and chemotactic peptides, decreases endothelin-1 expression, and inhibits platelet aggregation. This amino acid also improves endothelial function in patients with coronary artery disease and dilates human epicardial atheromatous coronary arteries. Despite the positive results from small case-control studies, it is still unclear whether chronic administration of L-arginine has any effect on clinical outcome in patients with coronary artery disease. In addition, other indirect strategies, such as the inhibition of arginase, could prove more effective at improving intracellular L-arginine bioavailability than exogenous L-arginine administration. The potential clinical usefulness of L-arginine, therefore, needs further evaluation in large, prospective clinical trials. Here, we present a critique of the existing literature about the role of L-arginine in the prevention of atherosclerosis.
M3 - SCORING: Zeitschriftenaufsatz
VL - 4
SP - 274
EP - 283
IS - 5
M1 - 5
ER -
